The next generation of the industry’s leading, clinically validated and scalable electroporation technology for complex cellular engineering.
- Rapidly transfect from 75 thousand to 20 billion cells
- 21CFR Part 11 enabled software
- Established regulatory path supported by FDA Master File
- Closed, cGMP-compliant, ISO-certified and CE-marked
- MaxCyte’s proprietary Flow Electroporation™ Technology